Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

A S Kubasch; P Peterlin; T Cluzeau; K S Götze; K Sockel; R Teipel; M Jentzsch; H Attalah; M Sebert; F Chermat; S Gloaguen; M Puttrich; M Cross; M Schneider; S Kayser; D Schipp; A Giagounidis; I Tirado-Gonzalez; A Descot; A van de Loosdrecht; A Weigert; K H Metzeler; P Fenaux; H Medyouf; U Platzbecker; L Ades

doi:10.1038/s41375-023-02029-1

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Leukemia. 2023 Nov;37(11):2309-2313. doi: 10.1038/s41375-023-02029-1. Epub 2023 Sep 21.

Authors

A S Kubasch^{1

2

3}, P Peterlin^{3

4}, T Cluzeau^{3

5}, K S Götze^{2

3

6}, K Sockel^{2

7}, R Teipel⁷, M Jentzsch¹, H Attalah⁸, M Sebert^{8

9}, F Chermat⁸, S Gloaguen^{2

3}, M Puttrich¹⁰, M Cross¹, M Schneider¹, S Kayser^{11

12}, D Schipp¹³, A Giagounidis^{2

3

14}, I Tirado-Gonzalez¹⁵, A Descot¹⁵, A van de Loosdrecht^{3

16}, A Weigert¹, K H Metzeler¹, P Fenaux^{3

8

9}, H Medyouf^#^{15

17

18}, U Platzbecker^#^{19

20

21}, L Ades^#^{3

8

9}

Affiliations

¹ Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.
² German MDS Study Group (D-MDS), Leipzig, Germany.
³ The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany.
⁴ Service d'hématologie Clinique, CHU de Nantes, Nantes, France.
⁵ CHU de Nice, Département d'Hématologie Clinique, Nice, France.
⁶ Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany.
⁷ Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany.
⁸ Groupe Francophone des Myélodysplasies, Paris, France.
⁹ Service d'Hématologie Seniors, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris and Paris Cité University, Paris, France.
¹⁰ GWT-TUD GmbH, Dresden, Germany.
¹¹ Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany.
¹² NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany.
¹³ DS-Statistics, Rosenthal-Bielatal, Germany.
¹⁴ Department for Oncology, Hematology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany.
¹⁵ Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
¹⁶ Amsterdam UMC, VU University Medical Center, Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.
¹⁷ Frankfurt Cancer Institute, Frankfurt am Main, Germany.
¹⁸ German Cancer Research Consortium, Frankfurt/Mainz partner site, DKFZ Heidelberg, Heidelberg, Germany.
¹⁹ Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.
²⁰ German MDS Study Group (D-MDS), Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.
²¹ The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.

^# Contributed equally.

No abstract available

Publication types

Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Benzocycloheptenes
Humans
Leukemia, Myeloid, Acute* / drug therapy
Myelodysplastic Syndromes* / drug therapy
Triazoles

Substances

bemcentinib
Benzocycloheptenes
Triazoles